Proposed NIH funding cuts are a pressing concern when one considers the broader impacts of reduced research funding.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric, small-molecule ...

Deep EigenMatics received the current U.S. patent (US 12,424,300 B1) for inventing a two headed neural network method for jointly generating the sequence and structure of a protein, given a condition ...

Vancouver company uses generative AI to identify potential molecules, saving millions of dollars and months compared to other ...

Artificial intelligence (AI) is rapidly transforming how scientific research is conducted, from accelerating model development to uncovering novel drug discovery pathways. However, with every promise ...

C4X Discovery Holdings PLC. C4X Discovery Holdings Ltd. C4X Discovery announces selection of a once-daily development ...

Drug development and production rely on stringent quality controls, reproducibility, and verification. Biopharmaceuticals, including protein-based therapies, require extensive characterization, ...

Thrombosis and hemostasis are vital processes preserving vascular health, with disruptions leading to debilitating and life-threatening disorders such as ...

Traditionally, developing a new drug takes many years and requires a massive financial investment, often involving significant risk and a high likelihood of failure. AI models trained on extensive ...

Global CRDMO platform integrating discovery, development, and manufacturing, with a diversified footprint across Asia, Europe ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

For one thing, BigBear.ai's revenue plunged 18% year over year in the second quarter of 2025. While Diebold Nixdorf's revenue also fell, the decline was only 2.6%. Importantly, the company's revenue ...